Join
Live feed
·
PRReleasevia Quantisnow
Abeona Therapeutics Inc. logo

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

ByQuantisnow·Wall Street's wire, on your screen.
ABEO· Abeona Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABEO (Abeona Therapeutics Inc.) and more on Quantisnow.